Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial

Target motion mitigation promotes high-precision treatment planning and delivery of extreme hypofractionated prostate cancer radiotherapy: Results from a phase II study

(2020) Carlo Greco et al.   RADIOTHERAPY AND ONCOLOGY

Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy

(2019) Deborah W. Bruner et al.   JAMA Oncology

Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline

(2019) Scott C. Morgan et al.   JOURNAL OF UROLOGY

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

(2019) Anders Widmark et al.   LANCET

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

(2019) Douglas H Brand et al.   LANCET ONCOLOGY

Ultrahypofractionation Should be a Standard of Care Option for Intermediate-Risk Prostate Cancer

(2019) A. Loblaw   CLINICAL ONCOLOGY

Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer

(2018) Karen E. Hoffman et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer

(2018) Himanshu R. Lukka et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial

(2018) Ruud C. Wortel et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial

(2018) Elke Rammant et al.   STRAHLENTHERAPIE UND ONKOLOGIE

Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer

(2017) Charles N. Catton et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer

(2016) W. Robert Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

(2016) Luca Incrocci et al.   LANCET ONCOLOGY

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

(2016) David Dearnaley et al.   LANCET ONCOLOGY

Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

(2016) Jenny L. Donovan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial

(2015) Shafak Aluwini et al.   LANCET ONCOLOGY

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

(2015) Anna Wilkins et al.   LANCET ONCOLOGY

Measuring health-related quality of life in men with prostate cancer: A systematic review of the most used questionnaires and their validity

(2015) Esther H.J. Hamoen et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study

(2014) Alan Jay Katz et al.   Frontiers in Oncology

An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer

(2008) George van Andel et al.   EUROPEAN JOURNAL OF CANCER

Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors

(2008) Martin G. Sanda et al.   NEW ENGLAND JOURNAL OF MEDICINE